Oxytocin vaginal - Peptonic Medical

Drug Profile

Oxytocin vaginal - Peptonic Medical

Alternative Names: oxytocin gel; oxytocin topical; Vagitocin

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Peptonic Medical
  • Class Hormones; Oxytocics
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atrophic vaginitis

Most Recent Events

  • 13 Jan 2017 Peptonic Medical completes enrolment in its phase II trial for Atrophic vaginitis
  • 21 Dec 2016 Peptonic Medical files patent applications for Oxytocin for Vulvar vestibulitis and Genital herpes
  • 24 Mar 2016 Peptonic Medical receives an approval from Swedish Medical Products Agency to initiate the planned phase IIb trial in Atrophic vaginitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top